NCT02552277View on ClinicalTrials.gov

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

March 7, 2017

Study Completion Date

October 30, 2017

Conditions
Diabetic NephropathiesPeripheral Nervous System Diseases
Interventions
BIOLOGICAL

PDA-002

PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.

DRUG

Placebo

Subjects will receive placebo administered on study days 1, 29, and 57.

Trial Locations (7)

32806

Compass Research, LLC, Orlando

33351

Infinity Clinical Research, LLC, Sunrise

77099

Nerve And Muscle Center Of Texas, Houston

78229

Endeavor Clinical Trials PA, San Antonio

92845

Collaborative Neuroscience Network, LLC- Southland Neurologic Associates - Los Alamitos, Garden Grove

92868

SDS Clinial Trials, Inc, Orange

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Celularity Incorporated

INDUSTRY

NCT02552277 - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter